The Vo lab is located in the Center for Translational Genomics at the Innovative Genomics Institute of UC Berkeley. Our goal is to leverage regenerative cell sources and CRISPR-based genome engineering to advance next-generation cell therapies for blood disorders, cancer and autoimmune disease.
We study cells of the blood system, one of the most highly regenerative tissues of the body. Blood is replenished throughout life by a small population of hematopoietic stem cells (HSCs), which reside in the bone marrow. Bone marrow transplant is the most established form of cell therapy and can cure many diseases such as sickle cell anemia, thalassemia, leukemia, lymphoma and primary immunodeficiency. However, the scarcity of primary HSCs limits their clinical use. We leverage the regenerative potential of induced pluripotent stem cells (iPSCs) combined with genome editing technologies to develop cell therapies for hematological disorders, cancer and autoimmune diseases.
— Quote from Damon Runyon Cancer Research Fellowship